Financial Performance - The company's revenue for Q1 2025 was ¥4,766,597,593.46, a decrease of 6.53% compared to ¥5,099,517,768.62 in the same period last year[5] - Net profit attributable to shareholders was ¥160,069,489.05, down 33.83% from ¥241,918,445.99 year-on-year[5] - The basic earnings per share decreased by 32.67% to ¥0.2733 from ¥0.4059 in the previous year[5] - Total operating revenue for the current period is $4.77 billion, a decrease of 6.5% from $5.10 billion in the previous period[26] - Net profit for the current period is $164.26 million, a decline of 33.3% compared to $246.31 million in the previous period[27] - Basic and diluted earnings per share decreased to $0.2733 from $0.4059, reflecting a 32.5% drop[28] Assets and Liabilities - The total assets at the end of the reporting period were ¥16,948,291,374.30, reflecting a slight increase of 0.70% from ¥16,830,316,478.61 at the end of the previous year[5] - The total current assets increased to RMB 9.99 billion from RMB 9.71 billion, with cash and cash equivalents rising to RMB 3.45 billion[22] - The total liabilities increased to RMB 9.28 billion from RMB 9.18 billion, with current liabilities accounting for RMB 7.68 billion[24] - Non-current assets decreased to RMB 6.95 billion from RMB 7.12 billion, with fixed assets valued at RMB 930.49 million[23] - The company's retained earnings increased to RMB 4.68 billion from RMB 4.52 billion, reflecting a growth in undistributed profits[24] Cash Flow - Cash flow from operating activities was ¥490,153,278.63, down 6.01% from ¥521,470,407.90 in the same period last year[5] - Net cash flow from operating activities is $490.15 million, down 6.0% from $521.47 million in the previous period[29] - Cash and cash equivalents at the end of the period totaled $1.61 billion, a decrease from $3.28 billion at the end of the previous period[30] - Cash recovered from investments increased by 499.00% to ¥1.20 billion, reflecting the recovery of principal from time deposits[13] - Cash paid for various taxes decreased by 66.98% to ¥97.79 million, primarily due to tax payments for the end of 2023[13] Investments and Financing - The company reported a significant increase in investment income of 319.29%, amounting to ¥1,397,240.69 compared to a loss of ¥637,173.05 in the previous year[12] - Cash paid for fixed assets and other long-term assets increased by 72.10% to ¥91.38 million, with ongoing projects in modern pharmaceutical logistics and digital manufacturing[13] - Cash invested in short-term time deposits surged by 33,128.57% to ¥1.16 billion[13] - Cash received from borrowings increased by 104.40% to ¥384.27 million, attributed to new stock repurchase loans[13] - The company has secured a stock repurchase loan commitment of RMB 135 million from Shanghai Pudong Development Bank for a three-year term[19] Shareholder Information - The total number of common shareholders at the end of the reporting period was 37,417[15] - The largest shareholder, Ruan Hongxian, holds 31.12% of shares, amounting to 182,245,290 shares[15] - The company has repurchased a total of 11,475,900 shares, representing 1.96% of the total share capital, with a total transaction amount of approximately RMB 149.99 million[20] - The company plans to use between RMB 80 million and RMB 150 million for share repurchase, with a maximum repurchase price set at RMB 19.02 per share[19] Operational Changes - As of March 31, 2025, the total number of stores decreased to 11,451 from 11,498, with 124 new openings and 125 closures during the period[17] - The company experienced a 47.07% decrease in tax and additional charges, totaling ¥5,478,936.82 compared to ¥10,351,529.70 last year[10] - The company’s long-term loans increased to ¥135,081,427.21 due to the addition of stock repurchase loans[9] - The company’s prepayments increased by 38.76% to ¥184,820,333.60, attributed to increased prepayments for goods by subsidiaries[9] Miscellaneous - The first quarter report of Yixin Tang Pharmaceutical Group Co., Ltd. is unaudited[31] - The new accounting standards will be implemented starting from 2025[31] - The financial statement items related to the first year of the new accounting standards will be adjusted at the beginning of the year[31] - The board of directors announced the first quarter report on April 25, 2025[31] - There are no specific performance summaries or user data provided in the document[31] - Future outlook and performance guidance are not detailed in the document[31] - No information on new products or technology development is mentioned[31] - Market expansion and mergers or acquisitions are not addressed in the document[31] - Other new strategies are not discussed in the document[31] - The document does not provide any financial figures or percentages[31]

一心为民 全心服务 股票代码：002727 股票简称：一心堂 公告编号：2025-022 号 一心堂药业集团股份有限公司 关于控股子公司四川本草堂药业有限公司 向银行申请授信额度提供担保的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 特别提示： 一心堂药业集团股份有限公司(以下简称"公司")本次为控股子公司四川本草堂药业有限 公司(以下简称"四川本草堂"或"债务人")提供连带责任保证方式的担保，被担保企业四川 本草堂最近一期经审计（2023年12月31日）的资产负债率超过70%，敬请投资者充分关注担保风 险。 一、担保情况概述 一心堂药业集团股份有限公司(以下简称"公司")于 2024 年 11 月 26 日召开第六届董事会 第十二次会议，于 2024 年 12 月 13 日召开 2024 年度第三次临时股东大会，审议通过《关于同 意子公司向相关银行申请综合授信额度并为其提供担保的议案》，同意公司担保下属子公司向 相关银行申请综合授信共计 13.68 亿元，用于子公司融资业务，具体额度在不超过 13.68 亿元 的金额上限内以银行授信为准，以上综合 ...

Core Viewpoint - The health awareness among the public is significantly increasing, leading to a growing demand for health services and products, positioning the big health industry as a comprehensive sector with vast future prospects [1] Group 1: Strategic Layout and Innovations - YXTT adheres to a full industry chain development model, integrating the entire process from raw material sourcing to retail and medical services [1] - The company has developed an online and offline integrated smart health service platform, expanding into diverse businesses such as health management, specialized medical services, and home-based elderly care [1] - YXTT has launched two sub-brands, "YXTT Health Management" and "YXTT Medical Care," to enhance service efficiency and customer experience in home and community elderly care [1] Group 2: Chronic Disease Management - YXTT has created a digital chronic disease management system that integrates comprehensive health management functions, enabling personalized consumer interventions [2] - The company has established a tiered pharmacist training system and developed standardized medication guidelines to enhance professional service capabilities [2] - These initiatives have improved service efficiency and consumer satisfaction, validating the innovative value of "technology empowerment, professional foundation, and ecological collaboration" [2] Group 3: Integration of Traditional Chinese Medicine (TCM) and Elderly Care - YXTT has established a care center in Kunming to provide lifecycle care services for the elderly, addressing the challenges of a shortage of professionals and weak grassroots service capabilities [2] - The company collaborates with Yunnan University of Traditional Chinese Medicine to cultivate interdisciplinary talents and enhance service efficiency through digital transformation [2] - YXTT is exploring new service scenarios by integrating TCM with tourism, developing "TCM health tourism" offerings [2] Group 4: AI Technology Integration - YXTT is leveraging vast data assets and AI models to build an intelligent supply chain for chronic disease management and health assistance [3] - The company is promoting an "AI Health Steward" model, creating a service loop that includes intelligent consultation, medication guidance, and health management [3] - YXTT aims to be a leader in the industry by enhancing the application of "artificial intelligence+" technologies to drive the upgrade of the big health industry [3] Group 5: Promoting Health Consumption - YXTT is working to shift health consumption in Yunnan from "optional" to "essential" by promoting health knowledge and services through initiatives like the "Health Journey" [4] - The company has developed a one-stop health service management platform to meet new demands from enterprises and employees, offering customized health management solutions [4] - YXTT is forming a "workplace-family-community" health network to extend individual health needs to group needs, creating a comprehensive health consumption ecosystem [4] Group 6: Economic Development and Employment - YXTT has established medicinal herb planting demonstration bases in 80 counties in Yunnan, injecting vitality into the local economy and increasing farmers' income [5] - The company provides numerous job opportunities, with an average of 36 stores in each county, contributing to local economic development [5] - YXTT's initiatives in herb planting and processing not only enhance local agricultural productivity but also create more employment opportunities [5] Group 7: High-Quality Development of TCM Industry - The Yunnan provincial government is implementing a three-year action plan for the high-quality development of the TCM industry, focusing on addressing pain points in seed quality, planting standards, and logistics [6] - YXTT emphasizes the need for precise coordination among the primary, secondary, and tertiary industries to avoid overproduction and ensure sustainable development [6] - The company advocates for resource integration through alliances to create a competitive advantage for the Yunnan medicinal herb brand [6]

登录新浪财经APP 搜索【信披】查看更多考评等级 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导性陈述或重大遗 漏。 特别提示： 经营范围：许可项目：药品批发；第三类医疗器械经营；食品经营；第二类增值电信业务；互联网信息 服务（依法须经批准的项目，经相关部门批准后方可开展经营活动，具体经营项目以相关部门批准文件 或许可证件为准）一般项目：第一类医疗器械销售；第二类医疗器械销售；消毒剂销售（不含危险化学 品）；卫生用品和一次性使用医疗用品销售；日用百货销售；化妆品批发；化妆品零售；会议及展览服 务；广告设计、代理；广告制作；广告发布（非广播电台、电视台、报刊出版单位）；企业形象策划； 市场营销策划；社会经济咨询服务；货物进出口；技术进出口；互联网销售（除销售需要许可的商 品）；品牌管理；信息咨询服务（不含许可类信息咨询服务）；农副产品销售（除依法须经批准的项目 外，凭营业执照依法自主开展经营活动）。 三、被担保方基本情况 企业名称：云南鸿云医药供应链有限公司 法定代表人：阮国伟 统一社会信用代码：91530100560058315X 企业类型：有限责任公司（自然人投资或控股的法人独 ...

一心为民 全心服务 一心堂药业集团股份有限公司 关于全资子公司云南鸿云医药供应链有限公司 向银行申请授信额度提供担保的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 特别提示： 股票代码：002727 股票简称：一心堂 公告编号：2025-021 号 一心堂药业集团股份有限公司(以下简称"公司")本次为全资子公司云南鸿云医药供应链 有限公司(以下简称"鸿云医药"或"债务人")提供连带责任保证方式的担保，被担保企业鸿 云医药最近一期经审计（2023年12月31日）的资产负债率超过70%，敬请投资者充分关注担保风 险。 一、担保情况概述 公司于 2024 年 11 月 26 日召开第六届董事会第十二次会议，于 2024 年 12 月 13 日召开 2024 年度第三次临时股东大会，审议通过《关于同意子公司向相关银行申请综合授信额度并为其提 供担保的议案》，同意公司担保下属子公司向相关银行申请综合授信共计 13.68 亿元，用于子 公司融资业务，具体额度在不超过 13.68 亿元的金额上限内以银行授信为准，以上综合授信在 一年范围内以银行授信为准。《关于同 ...

一心为民 全心服务 股票代码：002727 股票简称：一心堂 公告编号：2025-020 号 一心堂药业集团股份有限公司 关于控股子公司四川本草堂药业有限公司为下属子公司 提供担保的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 一、担保情况概述 一心堂药业集团股份有限公司(以下简称"公司"2024 年 12 月 13 日召开 2024 年度第三次 临时股东大会，审议通过《关于同意子公司向相关银行申请综合授信额度并为其提供担保的议 案》，同意公司控股子公司四川本草堂药业有限公司（以下简称"本草堂"）担保其下属子公 司绵阳本草堂药业有限公司（以下简称"绵阳本草堂"）向兴业银行股份有限公司成都分行申 请综合授信 1,000 万元，用于绵阳本草堂融资业务，具体额度在不超过 1,000 万元的金额上限 内以银行授信为准，以上综合授信在一年内以银行授信为准。《关于同意子公司向相关银行申 请综合授信额度并为其提供担保的公告》详见公司指定信息披露媒体《证券时报》《中国证券 报》《证券日报》和巨潮资讯网（www.cninfo.com.cn）。 二、担保事项进展情况 ...

一心为民 全心服务 股票代码：002727 股票简称：一心堂 公告编号：2025-020 号 一心堂药业集团股份有限公司 关于控股子公司四川本草堂药业有限公司为下属子公司 提供担保的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 一、担保情况概述 一心堂药业集团股份有限公司(以下简称"公司"2024 年 12 月 13 日召开 2024 年度第三次 临时股东大会，审议通过《关于同意子公司向相关银行申请综合授信额度并为其提供担保的议 案》，同意公司控股子公司四川本草堂药业有限公司（以下简称"本草堂"）担保其下属子公 司绵阳本草堂药业有限公司（以下简称"绵阳本草堂"）向兴业银行股份有限公司成都分行申 请综合授信 1,000 万元，用于绵阳本草堂融资业务，具体额度在不超过 1,000 万元的金额上限 内以银行授信为准，以上综合授信在一年内以银行授信为准。《关于同意子公司向相关银行申 请综合授信额度并为其提供担保的公告》详见公司指定信息披露媒体《证券时报》《中国证券 报》《证券日报》和巨潮资讯网（www.cninfo.com.cn）。 二、担保事项进展情况 ...

一心为民 全心服务 股票代码：002727 股票简称：一心堂 公告编号：2025-019 号 二、担保事项进展情况 （一）重庆鸿翔一心堂药业有限公司 1、近日公司与中信银行股份有限公司重庆分行签署了《最高额保证合同》，为全资子公司 重庆鸿翔一心堂药业有限公司(以下简称"重庆一心堂"或"债务人")提供连带责任保证，担 保的主债权本金余额最高额人民币 5,000 万元。 上述担保在已经审议的预计担保额度范围内，公司无需再履行审议程序。 2、被担保方基本情况 一心堂药业集团股份有限公司 关于子公司及其担保下属子向银行申请 授信额度提供担保的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 一、担保情况概述 一心堂药业集团股份有限公司(以下简称"公司")于 2024 年 11 月 26 日召开第六届董事会 第十二次会议，于 2024 年 12 月 13 日召开 2024 年度第三次临时股东大会，审议通过《关于同 意子公司向相关银行申请综合授信额度并为其提供担保的议案》，同意公司担保下属子公司向 相关银行申请综合授信共计 13.68 亿元，用于子公司融资业务，具 ...

一心为民 全心服务 股票代码：002727 股票简称：一心堂 公告编号：2025-018 号 一心堂药业集团股份有限公司 关于控股子公司四川本草堂药业有限公司 向银行申请授信额度提供担保的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 一、担保情况概述 一心堂药业集团股份有限公司(以下简称"公司")于 2024 年 11 月 26 日召开第六届董事会 第十二次会议，于 2024 年 12 月 13 日召开 2024 年度第三次临时股东大会，审议通过《关于同 意子公司向相关银行申请综合授信额度并为其提供担保的议案》，同意公司担保下属子公司向 相关银行申请综合授信共计 13.68 亿元，用于子公司融资业务，具体额度在不超过 13.68 亿元 的金额上限内以银行授信为准，以上综合授信在一年范围内以银行授信为准。《关于同意子公 司向相关银行申请综合授信额度并为其提供担保的公告》详见公司指定信息披露媒体《证券时 报》《中国证券报》《证券日报》和巨潮资讯网（www.cninfo.com.cn）。 二、担保事项进展情况 近日公司与上海银行股份有限公司成都分行签署了 ...

一心为民 全心服务 股票代码：002727 股票简称：一心堂 公告编号：2025-017 号 一心堂药业集团股份有限公司 关于回购股份方案实施完成暨股份变动的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 一心堂药业集团股份有限公司(以下简称"公司")于2025年2月10日召开第六届董事会第十 三次会议，审议通过《关于回购公司股份方案暨取得金融机构股票回购专项贷款承诺函的议案》， 该议案经出席本次董事会的董事人数超过董事会成员的三分之二审议通过。为维护公司价值及 股东权益所必需，同意公司使用自有资金及股票回购专项贷款资金以集中竞价交易方式回购已 发行的人民币普通股（A股）股票，回购资金总额不低于人民币8,000万元且不超过人民币15,000 万元（均含本数），回购价格不超过人民币19.02元/股。本次回购的股份将在披露回购结果暨 股份变动公告十二个月后采用集中竞价交易方式出售，并在披露回购结果暨股份变动公告后三 年内完成出售，若公司未能在上述期限内完成出售，未实施出售部分股份将履行相关程序予以 注销。本次回购股份的实施期限为自公司董事会审议通过回购股份方 ...